Baxter announces US launch of premixe...
Home  »  Community News  »  Baxter announces US ...
Apr
21
ragupathyrenganathan
Baxter announces US launch of premixed Vancomycin saline injection
Pharma News
0

Deerfield, Illinois
Wednesday, April 20, 2016, 18:00 Hrs  [IST]

Advancing Baxter’s longstanding commitment to provide hospitals with convenient presentations of medications that drive efficiency during drug preparation and enhance patient safety in administration, Baxter International Inc. announced the launch of a ready-to-use Vancomycin injection in 0.9% sodium chloride (normal saline) in 500 mg, 750 mg and 1 gram presentations. Vancomycin injection is an antibiotic used to treat serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci bacteria.

Baxter is the only manufacturer to offer Vancomycin in a premixed presentation, which uses the company’s proprietary frozen Galaxy container technology. Baxter’s innovative frozen premix technology is specifically designed for unstable molecules that are often administered using standardized doses. Premixed molecules offered in the Galaxy container are illustrative of the leading innovation in medical manufacturing that Baxter has been bringing to the healthcare industry for more than 80 years.

Vancomycin saline injection augments Baxter’s expanding portfolio of generic injectable drugs in the United States available in easy-to-use presentations that hospitals, physicians and patients can rely on because they are manufactured to the current good manufacturing practice (cGMP) regulations established by the US Food and Drug Administration (FDA). Premixed medications in standardized drug concentrations can help support hospitals’ goals for safe and efficient medication preparation because compounding is not necessary.

“As a company whose mission is focused on saving and sustaining lives, Baxter’s launch of Vancomycin injection in an innovative premixed saline presentation provides new options of an important antibiotic to address patient needs and demonstrates our commitment to making premixed preparations of medications more efficient for healthcare practitioners,” said Brik Eyre, president of Baxter’s Hospital Products business.

The launch is an extension of Baxter’s existing Vancomycin injection in 5% dextrose in 500 mg, 750 mg and 1 gram presentations and provides an alternative to certain patients who may need to avoid receiving additional dextrose. By providing Vancomycin in both saline and dextrose presentations, Baxter makes additional therapy options available of a critical antibiotic that has appeared on and off of the FDA Drug Shortage list.

Vancomycin saline injection is the second of nine clinically important molecules coming out of a collaborative partnership with Celerity Pharmaceuticals, LLC, a company of Water Street Healthcare Partners, to develop new products that use Baxter’s proprietary container technology, enhanced packaging platform, and aseptic filling manufacturing process.

Baxter’s Vancomycin saline injection in 500 mg, 750 mg and 1 gram presentations are available in the United States.

Courtesy – Pharmabiz



Leave a reply

You must be logged in to post a comment.